Although direct-to-consumer (DTC) pharmacy models have been around for years, they have gained traction in recent months, namely as the Trump Administration has made it easier for pharmaceutical manufacturers to participate. The Administration’s goal is to reduce drug costs by selling prescription drugs directly to patients, thereby circumventing pharmacy benefit managers (PBMs) and wholesalers. And so far, price-conscious, convenience-savvy consumers have been receptive.
But these programs come at a real cost, especially to independent pharmacies that rely on prescription volume, patient relationships, and clinical services to survive.
As these threats become real, community pharmacists can fight back by building visibility within their communities and promoting their essential role in today’s healthcare landscape. Technology can help. The comprehensive PrimeRx pharmacy software system, for example, facilitates patient/pharmacy engagement with the highest levels of workflow automation and functionality.
As a member of the RedSail Technologies network of 16,000+ community pharmacies, PrimeRx can help spread the word about the many services and programs unique to community pharmacy settings.
DTC models allow pharmaceutical companies and manufacturers to sell medications directly to cash-paying patients at discounted prices. “Patients pay out of pocket,” explains the American Journal of Managed Care (AJMC), removing the insurance component and eliminating the need to submit claims or seek insurer approval.”
According to IQVIA, pharmaceutical manufacturers that have launched DTC platforms include LillyDirect®, PfizerForAll™, and NovoCare®. These platforms, IQVIA notes, function as end-to-end digital ecosystems, “offering branded medications at discounted cash prices that bypass insurance.”
There are many reasons for the sudden interest in DTC programs:
While the DTC model has emerged as the “new shiny thing” in prescription medication purchasing, there are downsides, especially when it comes to implications for independent pharmacies. The National Community Pharmacists Association (NCPA) offered an apt assessment when it referred to TrumpRx as “dangerous,” and noted that it “appears to bypass the relationship between patients and their local physicians and pharmacists.” A website can’t monitor drug interactions, track patient history, or coordinate with physicians to manage chronic conditions, all things a local pharmacist does as a matter of routine.
Prescription dispensing accounts for 94% of pharmacy revenue, with razor-thin margins, any patient shift to DTC is immediately felt.
This comes as independent pharmacies already face PBM reimbursement pressures, DIR fees, and encroachment from chain competitors, leaving little room to absorb new disruption.
Pharmacists can be their own best advocates by spreading the word about what local pharmacies uniquely offer, like immunizations, blood pressure monitoring, diabetes education, smoking cessation, and point-of-care testing, all requiring in-person interaction that no DTC platform can replicate. While pharmacies can’t compete on cost, they can persuade patients with other selling points that include:
Fighting back against DTC doesn’t have to mean more work for already-stretched pharmacy staff. PrimeRx is built to help independent pharmacies do more with less, automating routine tasks while strengthening the patient relationships that DTC can never replicate.
The direct-to-consumer pharmacy model is a real and growing threat to independent pharmacies. And given today’s political and economic realities, the model is poised to have staying power, at least for the foreseeable future. But rather than throw up their hands, independent pharmacies can fight back.
Local pharmacies have much to offer, much more than a DTC program can ever hope to provide. With technology helping to lead the way, pharmacies can spread the word about these offerings and promote their essential roles as critical community members. The tools exist. The relationships are already there. Independent pharmacies that lean into both will not just survive, they’ll win.
No, but it is changing how prescriptions are distributed and increasing competition for patient relationships.
Yes, they can improve convenience for some patients but may reduce access to local pharmacist expertise.
Yes, by focusing on personalized care, community services, and efficient pharmacy technology.
Yes, pharmacists help identify drug interactions and manage medication histories.
Yes, modern pharmacy software improves workflow efficiency, compliance, and patient engagement.